Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03196895 · ClinicalTrials.gov registry record · NA
Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification
A NA study, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
- 192
- Enrollment target
NCT03196895: Completed NA study, sponsored by University of Virginia.
NCT03196895 is a NA study that has completed, run by University of Virginia. The registered enrollment target is 192 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03196895, a NA study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
- 192 participants
- Enrollment target
Study Summary
Conventional lifestyle modification in the management of type 2 diabetes focuses on weight loss, through caloric restriction and exercise, to reduce insulin resistance. This approach is limited because some people either do not need to lose weight, do not want to lose weight, cannot lose weight, or cannot maintain weight loss over a lifetime. This study proposes to evaluate the effectiveness of a lifestyle modification that focuses on reducing post-meal blood glucose (BG) elevations instead of weight loss. It works by teaching participants to: 1) choose low glycemic load foods that do not significantly increase their blood glucose, and 2) increase their routine physical activity after meals when it can offset post-meal blood glucose elevations. The study will also evaluate the role feedback about blood glucose fluctuations can play in improving the effectiveness of this program.
Primary Outcome
change in HbA1c from baseline measure
Interventions
- BEHAVIORAL Weight reduction training
- BEHAVIORAL PPG training
- BEHAVIORAL discrete BG feedback
- BEHAVIORAL continuous BG feedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2020-10-05 |
| Phase | NA |
What the finished NCT03196895 record still lists
NCT03196895 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 4 interventions - of which Weight reduction training is the first listed.
NCT03196895 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03196895 about?
NCT03196895 is a clinical study titled "Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification". Conventional lifestyle modification in the management of type 2 diabetes focuses on weight loss, through caloric restriction and exercise, to reduce insulin resistance. This approach is limited because some people either do not need to lose weight, do not want to lose weight, cannot lose weight, or ...
What is the current status of trial NCT03196895?
This trial is currently completed. It is a NA study. The enrollment target is 192 participants. The study started on 2017-06-28. Estimated completion is 2020-10-05.
What interventions are being tested in trial NCT03196895?
The interventions under investigation include: Weight reduction training (BEHAVIORAL), PPG training (BEHAVIORAL), discrete BG feedback (BEHAVIORAL), continuous BG feedback (BEHAVIORAL).
Who is sponsoring clinical trial NCT03196895?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03196895's enrollment target sits among peer trials
192 570th of 2000 higher than 1,427 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI